These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16434314)

  • 1. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG; Tarpey PS; Nacheva EP
    Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.
    Zagaria A; Anelli L; Albano F; Vicari L; Schiavone EM; Annunziata M; Pane F; Liso V; Rocchi M; Specchia G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):97-102. PubMed ID: 16737907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
    Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
    Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
    Pan J; Xue Y; Qiu H; Chen S; Zhang J; Wu Y; Shen J; Wang Y
    Cancer Genet Cytogenet; 2010 Dec; 203(2):333-40. PubMed ID: 21156255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients.
    Storlazzi CT; Specchia G; Anelli L; Albano F; Pastore D; Zagaria A; Rocchi M; Liso V
    Genes Chromosomes Cancer; 2002 Nov; 35(3):271-6. PubMed ID: 12353269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A molecular cytogenetic study on chromosome anomalies of chronic myeloid leukemia].
    Zhu B; Shen X; Li C; Lai X; Li Y; Shi K; Feng H; Wang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Apr; 17(2):116-8. PubMed ID: 10751535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present.
    Batista DA; Hawkins A; Murphy KM; Griffin CA
    Cancer Genet Cytogenet; 2005 Dec; 163(2):164-7. PubMed ID: 16337861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
    Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
    Aoun P; Wiggins M; Pickering D; Foran J; Rasheed H; Pavletic SZ; Sanger W
    Cancer Genet Cytogenet; 2004 Oct; 154(2):138-43. PubMed ID: 15474149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia.
    Yoong Y; VanDeWalker TJ; Carlson RO; Dewald GW; Tefferi A
    Eur J Haematol; 2005 Feb; 74(2):124-7. PubMed ID: 15654903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.
    Costa D; Carrió A; Madrigal I; Arias A; Valera A; Colomer D; Aguilar JL; Teixido M; Camós M; Cervantes F; Campo E
    Cancer Genet Cytogenet; 2006 Apr; 166(1):89-93. PubMed ID: 16616117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.